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Fingolimod (Gilenya; FTY720), a synthetic compound based on the fungal 
secondary metabolite, myriocin (ISP-I), is a potent immunosuppressant that was 
approved in September 2010 by the U.S. FDA as a new treatment for multiple 
sclerosis (MS). Fingolimod was synthesized by the research group of Tetsuro Fujita 
at Kyoto University in 1992 while investigating structure-activity relationships of 
derivatives of the fungal metabolite, ISP-I, isolated from Isaria sinclairii. Fingolimod 
becomes active in vivo following phosphorylation by sphingosine kinase 2 to form 
fingolimod-phosphate, which binds to specific G protein-coupled receptors (GPCRs) 
and prevents the release of lymphocytes from lymphoid tissue. Fingolimod is orally 
active, which is unique among current first-line MS therapies, and it has the potential 
to be used in the treatment of organ transplants and cancer. The first chapter 
reviews the discovery and development of fingolimod, from an isolated lead natural 
product, through synthetic analogues, to an approved drug.  
Natural products play an important role in the pharmaceutical industry, 
accounting for approximately half of all drugs approved in the U.S. between 1981 
and 2006.  Given the importance of natural product research and the vast amount of 
data that is generated in the process, it is imperative that the pure compounds and 
data are stored in a manner that will allow researchers to derive as much value as 
possible.  The field chemoinformatics, interchangeable termed cheminformatics, has 
set the standards for electronic storage of chemical data, as chemistry was one of 
the first scientific disciplines to pursue electronic means of data storage.  In this 
project an electronic database was created to capture all of the relevant data for 
each pure compound isolated via natural product research in Dr. Oberlies lab.  A 
system was also implemented to catalogue and store the compounds in an 
organized manner.    
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CHAPTER I 
MULTIPLE SCLEROSIS: THE DISEASE AND ITS CURRENT TREATMENT 
 
 
Over 2.5 million people worldwide suffer with the debilitating disease multiple 
sclerosis (MS). MS is a neurodegenerative disorder of the central nervous system that is 
estimated to affect twice as many women as men.1 The disease causes irreversible 
nerve damage, resulting in a wide range of symptoms, including fatigue, depression, 
pain, motor weakness, visual disturbances, and vertigo.1-3 The onset of symptoms is 
usually rapid and sudden, commonly appearing around age 30.1 The clinical course of 
MS varies greatly, from quickly progressive, resulting in clinical disability and possibly 
death, usually within 25 years,4,5 to recurring symptoms that reduce a patient’s quality of 
life, but without resulting in decreased life span. If untreated, approximately 50% of 
patients with MS are incapable of walking unaided within 15 years of disease onset.6,7  
The clinical course of MS is best predicted by the specific disease classification, 
either relapsing-remitting (RR), primary-progressive (PP), secondary-progressive (SP), 
or progressive-relapsing (PR).8 Approximately 85-90% of patients are diagnosed with 
RR-MS,9,10 defined by an ongoing and unpredictable cycle of acute episodes of 
symptoms followed by a distinguishable recovery period.8 The disease eventually 
becomes progressive in 30-40% of those diagnosed with RR-MS, changing their 
classification to SP-MS.6,10 For this, the relapse-recovery cycle may or may not continue, 
but the symptoms progressively worsen, which is atypical of RR-MS.8 With PP-MS, the 
disease continually, albeit gradually, progresses from onset.8 PR-MS is similar to PP-MS 
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in that the disease continually progresses in severity from onset, but with distinguishable 
relapses and possible recovery time in between episodes.8  
Autoimmune disorders, such as MS, are marked by defective immune system 
responses. MS occurs when T- and B-lymphocytes cross the blood-brain barrier, 
progress into the central nervous system, and attack healthy cells.11,12 Specifically, they 
destroy the myelin sheath and damage axons, resulting in inflammation.11 This in turn 
causes irreversible nerve and tissue damage and accounts for the wide range of 
symptoms observed in MS.11-13 
The cause of MS is unknown, but is believed to result from genetic predisposition in 
combination with environmental factors, which may include some type of infection.12 
However, to date, none of these factors have been proven to cause MS.12 Diagnosis is 
often based solely on the presence of the attributed disease symptoms and patterns.14 If 
a definitive diagnosis cannot be made from observable symptoms, magnetic resonance 
imaging (MRI) can aid in diagnosis.14 MRI scans of patients with MS show distinct 
plaques in the brain and spinal cord,12 usually measuring at least 3 mm in diameter.14  
Current medicinal treatment options for patients with MS include immunomodulators, 
immunosuppressants, and anti-inflammatory agents.15 Four different immunomodulators 
are approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing 
MS.16 Three are interferon betas (IFNβ) and include IFNβ-1b (Betaseron, Bayer 
HealthCare Pharmaceuticals) approved in 1993, IFNβ-1a intramuscular once weekly 
(Avonex, Biogen Idec) approved in 1996, and IFNβ-1a subcutaneously thrice weekly 
(Rebif, EMD Serono, Inc. and Pfizer Inc.) approved in 2002. The fourth 
immunomodulator, glatiramer acetate (GA) (Copaxone, Teva Pharmaceutical Industries, 
Ltd.), was approved in 1997. These four treatments, administered via either 
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subcutaneous or intramuscular injection, only modestly affect disease progression, with 
a 30% reduction in disease relapse rates being reported.15 The most commonly reported 
side effects include injection site reactions/necrosis and influenza-like symptoms.17-19  
Immunosuppressants are also used for treatment, with cyclosporin A20 (Neoral and 
Sandimmune, Novartis Pharmaceuticals), approved in 1983, and tacrolimus, also known 
as FK506,21,22 (Prograf, Astellas Pharma US, Inc.), approved in 1994, being the two 
most common. However, these agents cause complete suppression of the immune 
system, leaving the patient susceptible to life-threatening secondary infections.23 They 
also have toxic side effects at high doses, including renal impairment and kidney 
damage.24,25 In 2002 the FDA approved mitoxantrone (Novantrone, EMD Serono, Inc.) 
for treatment of worsening MS. Mitoxantrone has the properties of both 
immunosuppressants and immunomodulators, although its use is limited by 
cardiotoxicity.16  
In short, MS is a debilitating disease that often progresses, resulting in clinical 
disability. The current treatment options, while offering some benefits, are not ideal for 
myriad reasons. However, new treatment strategies may emerge due to the recent 
approval of fingolimod (1; Figure 1), given the trade name Gilenya by Novartis Pharma. 
The progenitor to fingolimod, myriocin (2, ISP-I; Figure 1), was discovered from a fungus 
and reported in 1972.26 To date, fingolimod has shown unprecedented efficacy for 
reducing annual relapse rates and symptoms,27-29 and combined with its oral 
bioavailability, it may become an important component in the arsenal to combat MS.  
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CHAPTER II 
DISCOVERY 
 
 
Cyclosporin A and FK506 were discovered initially as antifungal agents, and 
currently, both are clinically important immunosuppressants.20-22 Cyclosporin A was 
reported in 1976 from the fungus Trichoderma polysporum, which was later re-identified 
as Tolypocladium inflatum.20 FK506 was isolated from the bacterium Streptomyces 
tsukubaensis in 1987.21,22 The discovery and development of these compounds 
supported and validated the screening of fungi and other microorganisms in pursuit of 
new immunosuppressants.30  
During the late 1980s and early 1990s, Tetsuro Fujita and coworkers were also 
studying the fungus Tolypocladium inflatum.31 In these studies they isolated a cyclic 
depsipeptide that was an active antibiotic, which was reported previously from the 
fungus Isaria sinclairii.31 Fujita and colleagues thereafter focused their efforts on extracts 
of I. sinclairii.31  
Isaria sinclairii is native to Asia, mainly China, Korea, and Japan and is classified as 
an entomopathogenic fungus.32 It is the imperfect stage of Cordyceps sinclairii 
(Clavicipitaceae), and is closely related to Cordyceps sinensis Sacc., whose Chinese 
name, Dong Chong Xia Cao, means ‘winter worm, summer grass;’32 this species was 
reclassified recently to Ophiocordyceps sinensis.33 Fungal spores infect the larvae of 
suitable insect hosts, including members of the order Hymenoptera and Lepidoptera; the 
fungus is parasitic, growing within the host and resulting in death of the insect.32 The 
fungus completely colonizes the insect cadaver, and in the Spring and Summer white 
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fruiting bodies appear as stalks up to 6 cm in height.34 Fungi at this stage of 
development are regarded as mysterious and mystical in some Asian cultures and have  
been used for thousands of years in traditional Chinese medicine, as they are believed 
to impart eternal youth.32  
Fujita and colleagues31 utilized two assays, one in vitro and one in vivo, to evaluate 
the fungus and its metabolites. To screen for immunosuppressive activity, they used a 
mouse allogeneic mixed lymphocyte reaction (MLR) assay. In this in vitro assay, spleen 
cells from two different strains of mice (BALB/c and C57BL/6) are co-cultured and 
alloantigen added to stimulate T-cell proliferation.31 Samples were evaluated for 
inhibition of the proliferation of T-cells, with results reported as an IC50 value. The in vivo 
assay was performed by transplanting the dorsal skin of one rat (strain LEW) to the 
lateral thorax of a second rat (strain F344).35 Test compounds were administered 
intraperitoneally daily until the skin grafts were rejected, as evidenced by 90% 
necrosis.35 Compounds were scored based on their ability to prolong rat skin graft 
survival. Using these assays in concert was key to the eventual development of 
fingolimod.  
This evaluation process guided the isolation of a compound with immunosuppressant 
activity, which Fujita et al.31 termed ISP-I (2; Figure 1). Upon structure elucidation, they 
found ISP-I was identical to myriocin26 and thermozymocidine,36 which were isolated 
previously from Myriococcum albomyces and mycelia sterilia, respectively, via screening 
programs for antifungal agents.26,36 ISP-I was shown by Fujita et al. to be 5- to 10-fold 
more potent than cyclosporin A in the mixed lymphocyte reaction (MLR) assay,31 and at 
a dose of 0.1 mg/kg, ISP-I prolonged rat skin graft survival time by two days when 
compared to cyclosporin A at a dose of 1.0 mg/kg.35 However, ISP-I had some 
6 
 
unfavorable properties, being toxic to rats at a dose of 1.0 mg/kg, compared to 100 
mg/kg for cyclosporin A, and by poor solubility.35  
Researchers began to study ISP-I, with the goal of both simplifying the structure and 
improving the biological properties.37,38 Between 1995 and 1998, results from the 
evaluation of upwards of 50 analogues were reported.35,37-42 In the published results from 
both the in vitro and in vivo assays, the activity of the analogues of ISP-I were compared  
to the activity of cyclosporin A. Structure-activity relationship studies guided the 
synthesis of compounds that had simplified structures, improved physical characteristics 
(i.e. solubility), and more potent activity (Table 1).31,39 
The first analogue of interest was ISP-I-28 (3; Figure 1).41 ISP-I-28 contained the 
following changes from ISP-I: reduction of the 6-7 double bond and reduction of the 
carboxylic acid and the 14-ketone43 to alcohols. ISP-I-28 was less toxic than ISP-I (100 
mg/kg compared to 1 mg/kg, respectively).35 ISP-I-28 also prolonged rat skin graft 
survival time by two days, compared to cyclosporin A, both at a dose of 1.0 mg/kg, and 
ISP-I-28 was more soluble than ISP-I.35 However, ISP-I-28 was less potent than ISP-I in 
the MLR assay, with an IC50 value of 1630 nM compared to 3 to 8 nM, respectively 
(Table 1).35,42  
ISP-I-28 was simplified further by removing three hydroxy groups, leaving an 18-
carbon alkyl chain and resulting in the compound ISP-I-36 (4; Figure 1), which had an 
improved IC50 value (12 nM) in the MLR assay (Table 1).
41 ISP-I-36 also had improved 
activity in the rat skin graft assay, increasing the survival time by five days, compared to 
ISP-I-28, at a dose of 1.0 mg/kg. By shortening the carbon alkyl chain of ISP-I-36 from 
18 to 14 carbons, researchers generated ISP-I-55 (5; Figure 1), which was a more 
potent immunosuppressant in both the in vivo and in vitro assays. ISP-I-55 had an IC50 
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value of 5.9 nM (MLR assay) and more than doubled the survival time observed with 
ISP-I-36 in the rat skin graft assay (37.3 days with a 1.0 mg/kg dose; Table 1).35 
The final modification was the introduction of an aromatic moiety, which researchers 
believed would improve activity by restricting conformation,44 thereby leading to 
fingolimod (1; Figure 1). Positioning of the aromatic unit was critical, as its placement 
was shown to either decrease or increase immunosuppressant activity.39 By moving it 
one carbon position in either direction, there was greater than 10-fold loss of potency in 
the MLR assay.39 Moreover, the absorbance of the aromatic moiety in  
fingolimod was easy to detect analytically, a point that became beneficial in preclinical 
development studies.30 More importantly, when compared to ISP-I, fingolimod had 
improved activity, a more favorable toxicity profile, and more desirable physical 
properties, including increased solubility (Table 1).39,44 
A critical point in the discovery of fingolimod (1) was the use of the MLR assay to 
evaluate immunosuppressant activity.30 Alternatively, researchers could have used the 
serine palmitoyltransferase (SPT) inhibition assay, which evaluates immunosuppressant 
activity based on a compound’s ability to inhibit the enzyme serine palmitoyltransferase. 
Cyclosporin A, FK506 and ISP-I (2) are active in both the SPT and MLR assays.35,42 
However, the analogues ISP-I-55 (5) and fingolimod (1) only show activity in the MLR 
assay, suggesting that they operate via a different mechanism of action.35,42 If the SPT 
assay would have been used to evaluate the immunosuppressant capabilities of these 
compounds, both ISP-I-55 (5) and fingolimod (1) would have shown no activity35,42 and 
may not have been pursued further.30 The reported bioassay results for compounds 1-5 
and cyclosporin A are compiled in Table 1.  
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Figure 1. Studied Compounds that Lead to the Development of Fingolimod (1). 
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Table 1. Compiled Assay Results of Compounds of Interest in the Development of 
Fingolimod (1).  
 Assays Examineda 
Compound 
MLR Assay 
IC50 value 
(nM)35,39,41,42
Toxicityb
in 
vivo35,39,4
1,44 
Rat skin graft 
survival time 
(days) at 1.0 
mg/kg35,41,44 
Rat skin graft 
survival time 
(days) at 3.0 
mg/kg35,39,41,44 
Active 
in SPT 
assay35
,39,41,42,44
ISP-I (2) 3 to 8 1.0 toxic -- Yes 
ISP-I-28 (3) 1630 100 9.2 11.0 NRc 
ISP-I-36 (4) 12 10 14.8 17.6 NR 
ISP-I-55 (5) 5.9 10 37.3 45.5 No 
fingolimod 
(1) 
6.1 Cd 39.5 52.0 No 
cyclosporin A 14 100 7.3 10.8 Yes 
a Numerical values are as reported in the primary literature.  
b Concentration (mg/kg) at which animals died in the in vivo rat skin graft assay. 
c Not reported. 
d Contradictory; the published toxicity data on fingolimod are inconsistent at 10 mg/kg in 
this assay, with one paper reporting it as non-toxic,39 and a latter paper reporting it as 
toxic.44  
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CHAPTER III 
SYNTHESIS 
 
 
Fingolimod (1) was derived from ISP-I (2) (discussed above) but contains various 
synthetic alterations.37 At least 13 methods for the synthesis of fingolimod (1) and 
fingolimod-phosphate (6) have been developed. A detailed analysis of all of these is 
beyond the scope of this review. However, Table 2 provides a synopsis of the various 
synthetic strategies that have been published to date, and brief descriptions of a few are 
provided below.   
In 2004 Seidel et al.45 published an eight step method utilizing iron-catalyzed cross-
coupling reactions, starting from 2-(4-hydroxyphenyl)ethanol. They did not publish the 
overall yield of 1, but syntheses with similar methods have resulted in overall yields of 6 
to 24%.39,44 In 2005 a shorter synthetic method was published by Sugiyama et al.46 that 
required only five steps. The method was based on the Petasis reaction, which couples 
boronic acids, amines and carbonyls to give amino alcohols. The resulting overall yield 
of 1 was 28%.46 A seven step approach was published subsequently by Kim et al.47 that 
started with tris(hydroxymethyl)aminomethane (TRIS), which was converted to an 
aldehyde and then an alkyne. The alkyne was coupled to an aryl iodide via a 
Sonogashira reaction, hydrogenated, treated with acid and purified. This methodology 
was practical, inexpensive, and resulted in a 64% overall yield of fingolimod.47  
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Table 2. Highlights of Methods Used to Synthesize Fingolimod (1) and Fingolimod-P (6).  
Year Highlights of Method 
1995 First published method for the synthesis of fingolimod39 
2000 
Synthesis of fingolimod and analogues to evaluate immunosuppressive 
and lymphocyte-decreasing activity; method begins with Friedel-Crafts 
acylation of phenylalkyl acetates44 
2000 
Efficient 5-step method beginning with Friedel-Crafts acylation of 1-
phenyloctane; 13% yield48 
2001 
Method to synthesize fingolimod using MgSO4/MeOH/NaNO2 to 
regioselectively open the ring of an epoxide49 
2004 
Synthesis of both enantiomers of fingolimod-P; used L-serine derived 
oxazolizine to synthesize optically active intermediate, which was used to 
determine the absolute configuration of both enantiomers50 
2004 
Practical and scalable eight-step method based on iron-catalyzed cross-
coupling, starting with 2-(4-hydroxyphenyl)ethanol;45 similar methods have 
reported yields of 6–24%39,44 
2005 
Convenient five-step method based on Petasis reaction, using 
dihydroxyacetone, benzylamine and 2-(p-octylphenyl)vinylboronic acid; 
28% yield46 
2005 
Efficient and practical method to synthesize fingolimod-P based on 
monophosphorylation, using silver (I) oxide, tetrabenzyl pyrophosphate 
(TBPP) and tetrahexylammonium iodide51 
2005 
Practical asymmetric synthesis of both enantiomers of fingolimod-P based 
on lipase-catalyzed acylation, starting with N-acetylated fingolimod52  
2005 
Determined that fingolimod is phosphorylated in vivo to form only the (S)- 
stereoisomer; performed efficient synthesis of both enantiomers of 
fingolimod-P in optically pure form, starting with fingolimod53 
2006 
Concise and practical seven-step method using palladium-catalyzed 
Sonogashira cross-coupling reaction; 64% yield47 
2006 
Convenient synthesis of both enantiomers of fingolimod-P from p-
bromobenzaldehyde, using asymmetric Sharpless epoxidation54 
2008 
Convenient synthesis of immediate precursor of fingolimod, improving 1995 
method;39 precursor synthesized in 3 steps (vs. 6); yield of precursor 41% 
(vs. 18%)55 
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CHAPTER IV 
MECHANISM OF ACTION 
 
 
A recent review by Brinkmann et al.56 summarizes nicely the details of the 
mechanism of action of fingolimod. Briefly, the activation cascade of T- and B-cells 
begins with the phosphorylation of the sphingolipid, sphingosine (7; Figure 2), by 
sphingosine kinase 2, to form sphingosine 1-phosphate (S1P) (8; Figure 2).57 S1P is an 
activator of five different cell surface G-protein-coupled receptors (GPCRs), referred to 
as receptors S1P1-5, which regulate a variety of cellular processes.
58 S1P1-3 are 
expressed primarily on cells of the cardiovascular, immune, and central nervous 
systems, S1P4 is expressed primarily in lymphoid tissue, and S1P5 is expressed primarily 
in the spleen and central nervous system.58 Activation of these GPCRs is necessary for 
the body’s release of lymphocytes from the lymph nodes to the blood.59 
The improper response of lymphocytes, as occurs with MS, causes internal 
inflammation, cell apoptosis, improper neuron firing, and severe pain.15 Current medical 
treatments for MS, including cyclosporin A and FK506, act by inhibiting the enzyme 
serine palmitoyltransferase. Serine palmitoyltransferase is responsible for catalyzing the 
first step in sphingosine biosynthesis.23 Inhibition of this enzyme results in the body’s 
inability to produce sphingosine, preventing any activation of the GPCRs S1P1-5. 
Ultimately this inhibits the release of T- and B-cells, rendering the body incapable of 
generating an immune response to any stimuli.23  
Fingolimod (1) has a unique and novel mechanism of action. Once ingested, it is 
rapidly phosphorylated by sphingosine kinase 2 to form fingolimod-P (6; Figure 2).57,60 
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Fingolimod-P resembles the ligand S1P and competes with it to bind to four of the five 
S1P receptors.59 Fingolimod-P has the highest binding affinity for S1P1, binding to S1P3-5 
with slightly lower affinity, and has no affinity for S1P2.
53,61,62 Blood samples show that 
after 1 has circulated throughout the body, the concentration of fingolimod-P is up to four 
times that of the parent.62 This is essential for biological activity, as fingolimod itself has 
no binding affinity to any of the S1P receptors.53,61,62 
A study was conducted to compare the pharmacokinetics of oral vs i.v. 
administration of fingolimod.63 After i.v. administration, fingolimod (1) was present in the 
patient’s blood, but fingolimod-P (6) was not.63 Alternatively, during oral administration, 
presystemic phosphorylation of fingolimod to fingolimod-P may be a key, owning to the 
higher level of fingolimod-P measured after administration via this route.63 These 
observations suggest that sphingosine kinase 2, which phosphorylates fingolimod, is 
active during either (or both) first pass metabolism through the liver and/or the 
adsorption processes;63 it is known that sphingosine kinase 2 is highly expressed in the 
liver.64,65 
Ultimately fingolimod is metabolized in the liver, specifically by the cytochrome P450 
enzyme CYP4F, with a half-life of 5-6 days.66 It is metabolized primarily by oxidation of 
the hydroxy moieties into carboxylic acid derivatives and excreted in urine.67 Fingolimod 
undergoes a unique metabolic process, in which it is almost completely absorbed, slowly 
excreted and clearly favors oral administration of the drug. At present researchers are 
working to understand fingolimod’s metabolic process more fully.66,68  
Methods have been developed to synthesize fingolimod-P (6; Table 2); however, 
exploiting the body’s natural phosphorylation processes for converting 1 to 6 may be the 
best option clinically. For instance, when 1 is phosphorylated in vitro, both the (S)- and 
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(R)- enantiomers of fingolimod-P are produced. However, only the (S)-configuration has 
binding affinity to the S1P receptors.
40,53,61,62 Fortunately, phosphorylation of fingolimod 
(1) in vivo results in only the biologically active (S)-configuration being formed.53 
The novelty of the mechanism of action of fingolimod-P lies in its ability to redistribute 
the type of lymphocytes circulating in the blood, without reducing total lymphocytes. 
Central memory T-cells, which circulate regularly through lymph nodes,69 are believed to  
be the subtype that are auto aggressive in MS patients.58 Fingolimod-P (6) causes the 
lymphoid tissue to retain central memory T-cells, preventing them from entering into the 
blood.70 Concomitantly, 6 also causes the concentration of effector memory T-cells in the 
blood to increase.70 These latter T-cells do not circulate regularly through lymph nodes, 
and they are responsible for containing local pathogens and managing immune 
response memory.69 This unique redistribution is crucial, as it prevents neurological 
damage by central memory T-cells, while preserving many necessary functions of the 
immune system carried out by other lymphocytes.   
Fingolimod does not cause the destruction of any lymphocytes. Studies have shown 
that the overall count of lymphocytes circulating in the blood is reduced by approximately 
70% during fingolimod treatment, compared with lymphocyte levels prior to treatment.71 
This decrease is due to the retention of lymphocytes in the lymphoid tissue. Once this 
redistribution occurs, lymphocyte counts in the blood remain stable throughout treatment 
and return to normal levels within 4 to 8 weeks after treatment discontinuation.71  
Although fingolimod does not cause the destruction of lymphocytes, it does lead to 
degradation of the S1P1,3-5 receptors.
72 Binding of either S1P or fingolimod-P to S1P1,3-5 
receptors causes internalization of the receptor, moving it from the plasma membrane 
into the cell.73,74 Internalization of the receptor by S1P results in the receptor being 
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recycled to the cell surface within approximately 2 h.72 However, internalization caused 
by the binding of fingolimod-P (6) blocks the receptor recycling pathway and leads to 
receptor degradation.72,74,75 It takes 2 to 8 days after exposure to fingolimod-P for cells to 
recover normal expression of S1P1,3-5 receptors.
74 S1P1,3-5 receptor degradation likely 
contributes to the prolonged immunosuppressant activity observed with fingolimod.74,76,77 
This provides a benefit in that fingolimod’s activity is not dependent on the long-term 
stability of the compound in vivo, as short exposure time to fingolimod results in 
prolonged immunosuppressant activity.74   
16 
 
Figure 2. Mechanism of Phosphorylation via Sphingosine Kinase 2 (Adapted from Chun 
et al.58). The top shows the natural conversion of sphingosine (7) to sphingosine 1-
phosphate (8), while the bottom shows the formation of fingolimod-phosphate (6) from 
fingolimod (1). 
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CHAPTER V 
PHARMACOLOGY 
 
 
Fingolimod, given the trade name Gilenya by Novartis Pharma, is the first orally 
active treatment for MS.27 Two study groups, FREEDOMS (FTY720 Research 
Evaluating Effects of Daily Oral therapy in Multiple Sclerosis),29 and TRANSFORMS 
(Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting 
Multiple Sclerosis),28 published results of phase III clinical trials in February 2010. All of 
the completed clinical studies on fingolimod to date have been on those patients with 
RR-MS, although a phase III clinical trial (INFORMS study) was initiated in 2010 on 
those patients with PP-MS.78  
The FREEDOMS trial ran for 24 months and included a total of 1272 patients, 
approximately 70% of whom were female.29 All patients were 18 to 55 years of age and 
had relapsing-remitting (RR-MS). They were split into three treatment groups and 
administered daily either 0.50 mg of fingolimod (1), 1.25 mg of 1, or placebo. The 
primary endpoint of the study was annualized relapse rates. The secondary endpoints 
were the time to disability progression and the growth or generation of lesions, as shown 
by MRI.29 In this study the annualized relapse rate decreased 60% with a daily dose of 
1.25 mg of 1, and 54% with a daily dose of 0.5 mg of 1, relative to placebo.29 The 
probability of disability progression, confirmed after six months, was 12.5% for 0.5 mg of 
1, 11.5% for 1.25 mg of 1, and 19.0% for placebo.29 Similar proportions of patients 
reported adverse events in all three treatment groups.29 A few adverse events were 
18 
 
reported more commonly with 1 treatment, including lower respiratory tract infections, 
macular edema, and elevated liver-enzyme levels.29  
The TRANSFORMS study was conducted for 12 months and included 1292 patients 
between the ages of 18 and 55 who had RR-MS, approximately 67% of whom were 
female.28 Patients were split into three treatment groups and received a daily dose of 
fingolimod (1) of either 0.50 mg or 1.25 mg or a weekly subcutaneous 30 µg dose of 
IFNβ-1a. This study28 used the same endpoints as the FREEDOMS study.29 Progression  
of the disease to disability was infrequent in all three treatment groups, as would be 
expected given the 12 month timeline.28 Relapse rates were reduced by 38-52% in the 
fingolimod treatment groups vs the interferon IFNβ-1a treatment group.28 There were 
also significantly fewer new lesions and less lesion growth in the fingolimod groups 
versus the interferon IFNβ-1a group.28 Reported adverse events were similar to those 
reported in the FREEDOMS study, with the addition of localized skin cancer occurring in 
ten patients, eight of whom were undergoing treatment with fingolimod.28 The 10 
identified skin cancers were all excised successfully, did not appear to be related to the 
dose of fingolimod, and the data were not extensive enough to determine causality.28  
Fingolimod has been shown in both Phase III clinical trials,28,29 as well as in other 
clinical studies,63 to lower the patient’s heart rate by approximately 10% upon treatment 
initiation.67 Heart rate usually returns to its pre-treatment rate within 7 to 14 days after 
the first dose of fingolimod, and does not change again during continued treatment.67 
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CHAPTER VI 
OTHER PROSPECTIVE USES 
 
 
Fingolimod has the potential to be used in organ transplant. Researchers have 
suggested that it can prevent strong lymphocyte-mediated immune reactions in 
response to the implantation of new organs.59 Additionally, it has been suggested that 
fingolimod strengthens endothelial cells and preserves their function, although this has 
only been shown at concentrations that are, at a minimum, 5-fold higher than the dose 
administered normally.59 Regardless, these are promising concepts, as it implies that 
fingolimod may have other in vivo effects apart from the regulation of lymphocyte 
circulation.59  
Fingolimod (1) has been evaluated in vitro against three breast cancer cell lines 
(MCF-7, MDA-MC-231, and Sk-Br-3),79,80 two colorectal cancer cell lines (HCT-116 and 
SW620),79 and one prostate cancer cell line (LNCaP-AI).80 Fingolimod inhibited the 
growth of these cell lines at IC50 values in the range of 5 – 20 µΜ.
79,80 However, 
treatment of the three breast and two colorectal cancer cell lines with fingolimod-P (6) 
did not inhibit their growth.79 A new analogue, (S)-fingolimod vinylphosphonate, was 
evaluated in MCF-7 and LNCaP-AI cell lines and showed similar results to those of 
fingolimod.80 This suggests that fingolimod’s mechanism of action in cancer cell 
proliferation may not be the same as in MS, as only fingolimod-P is active in MS 
treatment. Fingolimod has also been evaluated in vivo in tumors derived from the 
MGC803 (gastric adenocarcinoma) cell line in nude mice.81 Mice were treated with 10 
mg/kg fingolimod daily and observed for 20 days.81 Fingolimod inhibited tumor growth 
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and did not cause any notable side effects.81 The potential of fingolimod to treat various 
types of cancer is an ongoing area of investigation.   
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CHAPTER VII 
CONCLUSION 
 
 
The discovery of fingolimod (1) was due largely to the persistence of the research 
group of Tetsuro Fujita. The lead natural product, ISP-I (2), which was isolated from 
Isaria sinclairii,31 gave them a framework to explore, particularly coupled with their clever 
and productive bioassay methodologies.31,35 Many analogues of ISP-I were tested before 
fingolimod was discovered with improved physical properties,37 a short synthetic 
method,47 and a novel mechanism of action.56,58 Fingolimod (1), under the trade name 
Gilenya, was first approved for use in Russia on September 10, 2010, and was 
subsequently approved by the U.S. FDA in September 2010 and by Europe’s European 
Medicines Agency (EMA) in March 2011.Europe’s EMA did initiate a review of Gilenya in 
January 2012 due to 11 reported patient deaths, but a causal relationship has not been 
established.82  European regulators have advised doctors to increase their level of 
monitoring of patients after administering the first dose of Gilenya, mainly due to the 
reported decrease in heart rate.82 
As Gilenya is the only current FDA approved first-line treatment for MS that is orally 
available, it has the potential to revolutionize the therapy of this debilitating disease.27-29 
Novartis reported in October 2011 that more than 25,000 patients have been treated 
with Gilenya and it has been lauded by some as one of the top ten medical inventions of 
2011.83 Given this impact, it was estimated that Novartis may profit upwards of $1 billion 
annually from sales of Gilenya,84 adding it to the long list of natural product inspired 
blockbuster drugs.85,86 Future research on 1 will likely focus on more detailed analysis of 
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its mechanism of action, while continuing to test it for the treatment of other diseases. 
Moreover, there are certainly other research groups looking to develop second- and 
third-generation analogues that further enhance potency and/or minimize side effects.  
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CHAPTER VIII 
 
INTRODUCTION AND BACKGROUND 
 
 
Natural products play an important role in the pharmaceutical industry.85  Natural 
products have many chemical advantages, including being good scaffolds for drug 
design, as they are known to provide molecular diversity.87  Additionally, when compared 
to synthetic drugs, natural products tend to be more readily absorbed in vivo.87   
It has been estimated that approximately 25-50% of all drugs marketed in the U.S. in 
2010 originated as natural products.88  More specifically, approximately half of all drugs 
approved in the U.S. between the years 1981 and 2006 were either natural products, or 
based on natural products.85  Natural products have made a significant contribution to 
the treatment options of many widespread diseases, particularly bacterial infections and 
cancer.85  Of all antibacterial and anticancer drugs approved between the years 1981 
and 2006, approximately 78% of them were either derived from, based on, or itself a 
natural product.85   
Natural products are derived from a wide range of source organisms, including fungi, 
bacteria, plants, amphibians and marine organisms.  Fungi produce secondary 
metabolites that have a long history of providing the scientific community with 
biologically active and structurally diverse chemical compounds.  It has been estimated 
conservatively that 1.5 million species of fungi exist in the world today,89 with more 
aggressive estimates predicting up to 5.1 million species.90  Of these species, only 
approximately 100,000 have been described taxonomically.91  This leaves the majority of 
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fungal species as yet to be studied, pointing to the importance of natural products 
research programs aimed at studying fungi and their secondary metabolites.   
According to a search conducted on February 12, 2012 in the Dictionary of Natural 
Products, there are 243,250 natural product compounds that have been characterized 
worldwide.  Of these, 13,298 were isolated from fungi.  To date, approximately 150 pure 
compounds have been isolated from fungi in Dr. Oberlies lab, equating to roughly one 
percent of the world’s supply of fungal secondary metabolites.   
Conducting natural product research generates a large amount of data.  First, 
extractions are done to remove secondary metabolites from the organism serving as the 
source.  The extractions contain a mixture of compounds, which go through bioassays to 
screen for biological activity.  Approximately five percent of the extractions show 
biological activity and make it past this stage of research.  The extractions that present 
biological activity must then undergo fractionation to begin untangling the web of mixed 
compounds.  Another round of bioassays are conducted to evaluate the individual 
compound’s activity.  The compounds that show activity in the bioassays are then 
purified and their structure elucidation process begins.  This phase of research includes 
many techniques, such as mass spectrometry (MS), nuclear magnetic resonance (NMR) 
spectroscopy, high performance liquid chromatography (HPLC) and liquid 
chromatography/mass spectrometry (LC/MS).  The use of these tools often results in the 
elucidation of a lead structure, which is then studied and refined for many years before it 
likely can be considered as a potential drug. 
Given the importance of natural product research and the vast amount of data that is 
generated in the process, it is imperative that the compounds and data are stored in an 
organized manner that will allow researchers to derive as much value as possible.  
25 
 
When determining the method for data storage, it is important to consider many factors.  
First, the data should be stored in a manner that will allow it to be readily accessible to 
those who need it, in this case being all of those working in Dr. Oberlies research group.  
Second, once stored, it should be easy to retrieve and make use of any particular piece 
of data.  Moreover, as people frequently come and go from University research groups, it 
is important to have a standard data storage process that is easy to learn and use. 
Keeping detailed laboratory notebooks is a universal data storage method for 
chemists.  However, they are organized chronologically, and after only a few years of 
research the amount of time required to find one specific piece of data is extensive and 
impractical.  Likewise, from a time and feasibility standpoint, it is not possible to build 
relationships between similar types of data generated over the lifetime of the lab.  
Therefore, it is now widely accepted that electronic storage of chemical research data is 
necessary to allow the data to be easily shared, retrieved and ultimately useful.92 
One of the first scientific disciplines to pursue electronic means of data storage was 
chemistry.92  Development in this field was undoubtedly motivated by constant growth in 
the amount of data generated by chemists.  The earliest example comes from a 
publication in 1946 by King et al.93 that describes a method of using punched cards to 
solve long calculations that ultimately aided them in generating and evaluating band 
spectra of asymmetrical rotors.94  The Chemical Abstract Service (CAS) of the American 
Chemical Society was instrumental in furthering research in using computers to store 
chemical data throughout the 1950s.94   
One key challenge that presented itself was the need for a method to store chemical 
structures electronically, as early computers operated solely with textual “alpha numeric” 
information.95  CAS is credited with being the first to store chemical structures as 
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computer files that were searchable, in the 1960s.  Progress throughout the 1970’s 
included the development of methods to search databases for compounds based on 
their crystallographic data, an advancement that allowed researchers to select 
compounds based on their three-dimensional motif.96 
The American Chemical Society first dedicated a journal to the importance of 
computerized storage of chemistry-related information in 1961 titled the Journal of 
Chemical Documentation.95  As the field has evolved, the name of the journal has 
changed to the Journal of Chemical Information and Computer Sciences in 1975, and in 
2005 to the Journal of Chemical Information and Modeling.95   
The change in name of the journal representing this field is characteristic of the 
evolving name of the discipline itself.  Until the late 1990’s, the discipline was referred to 
interchangeably as chemometrics, computer chemistry and chemical informatics.94  
Societies of chemometrics and universities with “computer chemistry” in their name 
coexisted94 and were focused mainly on making predictions about chemical data by 
applying statistical analysis to chemistry databases.96  The term chemical informatics 
was used to describe the merging fields of chemistry and information technology.96 
Concurrently, in 1976 the discipline of biology began using the term bioinformatics to 
describe the application of information technology to biology.94  In 1998 Dr. Frank Brown 
first introduced the term chemoinformatics and defined it as “the mixing of those 
information resources to transform data into information and information into knowledge 
for the intended purpose of making better decisions faster in the arena of drug lead 
identification and optimization”.97  Today, chemoinformatics is used interchangeably with 
the term cheminformatics.  However, the original definition has been expanded so as not 
to be limited to the process of drug discovery.96 
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A common example of utilizing chemoinformatics to aide in drug design is screening 
a virtual library of compounds for their ability to perform a targeted activity.  In this 
example, researchers would build a virtual library of compounds that have been or could 
be synthesized.  If they have information such as the crystal structure of a targeted 
enzyme, they could let a computer virtually screen the library for a compound that would 
bind to the active site.  With their lead compound identified, they could synthesize it and 
begin the next step in their drug discovery process. 
Using natural products as a source of drug discovery adds another dimension to the 
use of chemoinformatics.  In this process, researchers conduct field collections to obtain 
a variety of organisms.  Secondary metabolites from the organism are extracted in 
complex mixtures and usually undergo multiple fractionations until the compounds are 
purified.  They are then assayed, and researchers may not determine the full chemical 
structure until after they receive assay results. 
In this instance, chemoinformatics can be applied as a method to store all of the data 
generated in the discovery process, while easily revealing relationships between the 
data that might not otherwise be obvious, hence transforming “data into information and 
subsequently into knowledge”.  This application of chemoinformatics can likewise guide 
the research being conducted.  A major goal of the project described herein was to apply 
the principles of chemoinformatics to the research conducted by Dr. Oberlies lab group 
through the design and implementation of a computer database. 
The secondary goal was to create an organized system for storing all of the pure 
compounds in Dr. Oberlies lab.  Currently, each chemist in this lab follows their own 
method of compound storage, as shown in figures 3 and 4.  This has led to 
disorganization, as only the original chemist can find any isolated pure compound.  Each 
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of the isolated pure compounds is the product of weeks, if not months, of research time 
and tens of thousands of dollars of research grants.  If a pure compound cannot be 
located within the lab, all of the research time and money is lost.  Given the resources 
expended while isolating and characterizing these compounds, it is also critical to derive 
as much value as possible. 
Dr. Oberlies research group pursues the discovery of new anticancer drug leads, and 
therefore screens compounds using a battery of anticancer bioassays.  Other 
researchers around the world are studying a wide variety of human and animal diseases 
and utilize hundreds of other bioassays.  It is very probable that in the future Dr. Oberlies 
lab may be interested in looking for drug leads for different diseases or may be using 
different bioassays to screen for anticancer activity. 
Having the already isolated pure compounds stored in an organized manner will 
allow them to be leveraged into different bioassays in the future, increasing the 
productivity of the time and money spent on natural products research.  An example of 
this was published by Dr. Matthias Hamburger and collaborators as they looked for 
natural product compounds that displayed potent HIV inhibition activity.98  As a result of 
previous research, the authors had a library of over 800 plant and fungal extracts readily 
accessible.  Instead of trying to duplicate years of expensive and time-intensive lab work 
extracting secondary metabolites from various organisms, they screened small aliquots 
of each extract in their cell-based antiretroviral bioassay.98  This produced four 
daphnane diterpene compounds that inhibited the replication of HIV-1 while displaying 
no cytotoxicity at the concentrations tested.98  More importantly, having a physical library 
of extracts on-hand allowed them to capitalize on research already conducted and derive 
the greatest value from their research.      
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Figure 3.  Various Storage Methods Currently Utilized in Dr. Oberlies Lab. 
 
 
 
 
Figure 4.  Example of Hand-written Labels on Boxes of Pure Compounds in Dr. Oberlies 
Lab. 
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Figure 5.  Example of Various Vial Labeling Methods Currently Utilized in Dr. Oberlies 
Lab. 
 
 
 
 
Figure 6.  Example of Hand-written Labeling by Chemist in Dr. Oberlies Lab. 
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CHAPTER IX 
METHODS 
 
 
Database:  All software used to populate the database was purchased from 
Advanced Chemistry Development, Inc. (Toronto, Ontario, Canada). The program in 
which the database was created was ACD/Spectrum Database, Product Version 12.5, 
ACD/Labs Release 12.00. Structures in the database were uploaded from 
ACD/ChemSketch. ACD/ SpecManager was used to process and upload spectroscopic 
data into the database.   
Fields in the Record User Data and Document User Data windows of  
 
ADC/Spectrum Database were customized to capture the information that is specifically  
 
relevant to natural product research.  The customized fields are as follows: 
 
 
Record User Data 
Compound Name 
Notebook ID 
Specimen Number 
Compound Amount 
Project 
Chromatogram 
PDA Spectrum 
1H 
1H NH 
13C 
COSY 
HSQC 
HMBC 
NOESY 
ROESY 
Crystal Picture 
Compound Storage 
Crystal Structure 
Publication 
Chemist 
Entered by 
Date 
Date Modified 
 
32 
 
 
Document User Data 
Sample No. 
 
Collection Site 
 
Collection Country/State 
 
Genus_species 
Order 
 
GenBank Accession No. 
 
IC50 MCF-7 
 
IC50 H460 
IC50 SF268 
 
IC50 HT-29 
 
IC50 MDA-MB-435 
 
IC50 NF-kB 
 
   
Compound Storage:  The pure compounds are stored in 8 mL clear glass E-Z 
Ex-Traction vials, product W224618, purchased from Wheaton Industries, Inc. via Fisher 
Scientific.  These vials were selected because they are the appropriate size, fit properly 
into vial files and are uniquely different from any other vial currently used in Dr. Oberlies 
lab.  The vials are stored in an M-T Vial File, product W228790, purchased from 
Wheaton Industries, Inc. via Fisher Scientific.  The vials were labeled with labels created 
via LabelView software produced by Teklynx International.  
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CHAPTER X 
DATABASE RESULTS 
 
 
As of February 17, 2012 the database contained 116 records, each of which  
 
represents one pure compound isolated in Dr. Oberlies lab.  Multiple telephone calls  
 
were made to Advanced Chemistry Development, Inc. to determine how to fix minor  
 
software issues and adjust ACD/Spectrum Database settings.  Approximately thirty-five  
 
compounds were initially entered to allow for testing and configuration of the database.   
 
Next, a protocol was written detailing how the database should be populated.   
 
Researchers in the lab who had compounds to be entered into the database were  
 
provided with the written protocol and one-on-one support to facilitate the entry of all  
 
data.  Researchers gave feedback on the protocol, which was revised and clarified  
 
where needed.  The final version of the written protocol is as follows. 
 
 
Written Protocol for Entry of Data into Database 
 
 
1     BEFORE YOU BEGIN 
**IMPORTANT:  BACK-UP DATABASE**   NEVER SKIP THIS STEP 
The database is currently stored on the N drive, accessible only to the Oberlies research 
group.   
To get to the database: 
1. From your computer tabs, click on Computer. 
2.  Click on N directory (ChemBioChem) 
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3. Click on Custom folder. Here you will see the Oberlies lab group folder. Click on it and 
you will see the ACD database folder. 
To back-up the database: 
1. Right click on the database file and select “Copy” 
2. While in the same folder on the N directory, again right click and select “Paste” 
3. The file name should become “Copy of Oberlies Lab”.  Right click this file and select 
“Rename”.  Rename the file “Backup mm-dd-yr Oberlies Lab” with dd-mm-yr 
indicating the current date. 
Note:  Once you create a back-up file of the database, leave it alone.  Work from the 
original “Oberlies Lab” file.  The back-up file will be kept indefinitely and is to be used 
only to correct unfixable mistakes (such as the deletion of a record). 
2     OPENING DATABASE 
Open ACD’s Spectrum Database.  Click “Database” on the toolbar, and then “Open”.  To  
 
locate the database file, select the N drive, open the Custom Folder and then Oberlies  
 
Lab Group folder. 
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3     ADDING A NEW RECORD 
Database always opens in Browse Mode (read only).  To edit database, click “Database”  
 
on the toolbar, then “Update Mode”.  
 
 
 
 
 
Click “Record” on the toolbar, and then “New”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
You now have a blank record.  Each record should correspond to 1 pure compound.  
You will need to import all available data for this compound (NMR, MS, etc.), import 
a structure (if known), populate the “Document User Data” fields and the “Record 
User Data” fields for your compound in this 1 record.  If any of this information is 
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unknown, leave the field blank.  NEVER add information to this database that you 
do not believe is 100% accurate! 
4     ADDING SPECTRA TO A RECORD 
On the bottom left of the database window, select “Processor”. 
 
 
 
 
 
When the window shown below appears, make sure that “Open an Existing File” is  
 
selected, and then double click “More files”. 
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Alternatively, to open a data file when this window does not appear, click the red file icon  
 
in the upper left corner of the processor screen.   
 
 
 
 
 
 
 
 
 
 
 
Locate the desired file and then click “Open”. 
 
 
 
 
 
**If 1H spectra appears as FID (unprocessed), click “Interactive FT”.   
 
 
 
 
 
 
 
 
 
 
When the box below appears, click “OK”. 
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Next, click “Phase” and then “Autosimple” as shown below. 
 
 
 
 
 
 
 
 
 
 
 
Once the file is opened and processed, click the green icon shown below to upload  
 
the file to the database. 
 
 
 
 
 
If this warning appears, click “OK”:  
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When the box shown below appears, be very intentional about your selection. 
 
 
 
 
 
(a) Attach Spectrum to Currect Record adds the file to the record you are viewing in 
the database   
(b) Append Spectrum as New Record creates a new, blank record and adds your 
selected file.  If you have already created a new record, you should choose option 
(a).  
Note: If you are uncertain about which record you are currently viewing in the database, 
do not proceed.  Click cancel, go back to the database window (by clicking the Database 
tab on the bottom left) and make sure you are uploading the correct file to the correct 
record. 
Once you click “OK”, you will automatically go from the Processor to the Database and 
should see your uploaded file.  Repeat these steps to add all files relevant to your 
compound. 
5     ADDING A STRUCTURE TO THE RECORD 
On the bottom left of the database window, select “ChemSketch” 
40 
 
 
 
 
Once in ChemSketch, either open a file of your structure, draw the structure, or copy the  
 
structure and paste into ChemSketch.  
 
To upload the structure to the database, select the tab labeled “Structure” on the bottom  
 
left of the screen.  Then select “Attach Structure to the Current Record”. 
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Note: If you are uncertain about which record you are currently viewing in the database,  
 
do not proceed.  Go back to the database window (by clicking the Database tab on the   
 
bottom left) and make sure you are uploading the correct structure to the correct record. 
 
Once you click “Attach Structure to the Current Record”, you will automatically go from  
 
ChemSketch to the Database and should see your uploaded structure. 
 
6     ADDING RECORD USER DATA  
Under the “Record User Data” heading, double click the line that says “Double-click to 
enter new data item”.  In the pop-up box that says “Select Data Name”, click the field 
that you wish to enter and then click “OK”. 
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The following box will appear.  
 
 
 
 
 
(a) Value:  to enter any alpha-numeric information, leave the selection as “Value”,  
 
enter the information and click “OK”. 
 
(b) Link to File/Database/URL:  only link files (not URL) in this database.  Files to 
be linked include a pdf of the publication corresponding to the compound or any 
NMR/MS/Chromatogram files that are a pdf.   
(c) To link a file to the database:  
1. Find the appropriate file on your computer.  Right-click the file and select 
“copy”.  Then, navigate into the N directory, click on “Custom Folder”, 
“Oberlies Lab Group” and then “Linked Database Files”.   
2. If there is not a folder for the Fungus Number of the organism for the 
compound you are entering, right click and select “New”, “Folder” and enter 
the Fungus Number as the folder name 
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3. In that folder, again right click and select “New”, “Folder” and enter the 
Notebook ID as the folder name. 
4. Right-click and paste your file in the folder you created for the Notebook ID.  
Repeat this process for all files you would like to link. 
5. In the database, select “Link to File/Database/URL” instead of “Value” 
6. Click “Browse”.  Browse to the file you pasted on the N directory.  Select “OK” 
Repeat this process to enter all of the known pieces of information in the Record User 
Data window.  If a particular field is unknown, do not add it to the record.  If you are 
entering multiple new records containing a lot of the same record user data, it is possible 
to right-click in the record user data window, select copy and then paste into your next 
record.   
Example and format of Record User Data Fields: 
Compound Name: Zeaenol 
Notebook ID: 01003-47-2 (if 2, separate by a comma and space) 
Specimen Number: MSX63935 (if 2, separate by a comma and space) 
Compound Amount: 5.26 mg 12/06/2011 (total amount of compound in lab & date) 
Chemist: Sloan Ayers (person in lab that isolated compound) 
Entered by: Cherilyn Strader (your name, or person that is entering compound in 
database) 
Date: 7/26/2011 (date compound is entered into database) 
Compound Storage: 2 vials 1B3 2E8 (number of and location of vials in lab) 
Publication: (Link) 
1H: (Link) 
13C: (Link) 
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HMBC: (Link) 
HSQC: (Link) 
1H NH: (Link) 
Chromatogram: (Link) 
Project: KinghornP01 CA125066 
Plate Cell #: Do not enter 
7     ADDING DOCUMENT USER DATA 
Under the “Document User Data” header, follow the same process as entering Record 
User Data.  If a particular field is unknown, do not add it to the record.  If you are 
entering multiple new records containing a lot of the same document user data, it is 
possible to right-click in the document user data window, select copy and then paste into 
your next record.   
Example and format of Document User Data Fields: 
Sample No: G12345 
Collection Site: Agricultural Farms, Univ of Nigeria 
Collection Country/State: Nigeria 
Genus_species: Phoma clematidina 
Order: Pleosporales 
GenBank Accession No: JF767207 
8     HELPFUL INFORMATION ABOUT EDITING DATABASE 
Saving:  The database automatically saves every change you make.  When you are 
finished working, simply click the red “X” in the top right-hand corner to close the 
database. 
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Appearance of Structure:  Sometimes the database displays the structure a little 
differently than you may have entered it into ChemSketch.  For example, a terminal CH3 
may be displayed as a straight line or two labeled –OH groups that are close together in 
the ChemSketch structure may overlap each other in the database view.  You can right-
click on the structure in the database and click “delete”, tweak your drawn structure in 
ChemSketch and then upload it again to make small changes. 
Structure User Data:  When you upload a structure, the database automatically  
 
displays the formula and calculates the formula weight.  If you know the compounds  
 
exact mass, enter it in the Structure User Data window. 
 
 
 
 A user-guide was also written that details how to perform searches within the  
 
database.  This user guide is as follows. 
 
 
Written User-Guide to Facilitate Searching the Database 
 
 
1     SEARCHING BY ALPHA-NUMERIC INFORMATION 
First, ensure that the database is in “Browse Mode”.  To do this, click “Database” on the  
 
toolbar.  You should see a check beside “Browse Mode”.  If you do not, click “Browse  
 
Mode”. 
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To search by a Record User Data or Document User Data field, on the top menu select 
 
 “Search” and then either “Record User Data” or “Document User Data”. 
 
 
 
 
 
Multiple search options are then presented.  Under “Data Name(s)” select the field you  
 
wish to search, or select “All Fields”.   
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Then select the search condition.  If you are looking for a specific piece of information,  
 
select “Exact”.  The database will then find exact matches of the alpha-numeric text you  
 
enter in the specified Data Name (field). 
 
 
 
 
 
 
 
 
 
To search by multiple conditions, select “More”.  To undo, select “Less”. 
 
 
 
 
 
When you are ready to execute the search, select “OK”. 
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A pop-up box will display, showing how many results your search produced. Select “OK”  
 
to scroll through the results. 
 
 
 
 
 
When you are finished viewing your search results, on the top menu select “Search” and  
 
then “Retrieve All” to view all records in the database. 
 
 
 
 
 
2     SEARCHING BY STRUCTURE 
First, ensure that the database is in “Browse Mode”.  To do this, click “Database”  
on the toolbar.  You should see a check beside “Browse Mode”.  If you do not, click  
“Browse Mode”. 
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On the bottom left of the database window, select “ChemSketch” 
 
 
 
 
 
Once in ChemSketch, draw the full structure or sub-structure that you want to search for.   
 
When completed, click the “Search” tab on the bottom of the screen, and then select  
 
either “Substructure”, “Exact structure” or “Similar Structure”. 
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A pop-up box will display, showing how many results your search produced. Select “OK”  
 
to scroll through the results. 
 
 
 
 
 
When you are finished viewing your search results, on the top menu select “Search” and  
 
then “Retrieve All” to view all records in the database. 
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3     SEARCHING MULTIPLE DATABASES 
First, ensure that the database is in “Browse Mode”. To do this, click “Database” on the  
 
toolbar.  You should see a check beside “Browse Mode”.  If you do not, click “Browse  
 
Mode”. 
 
 
 
 
 
On the top menu, select “Search” and then “Define Multiple DB List”. 
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A pop-up box will display.  Make sure that there is a check in the box to the left of 
 
“Execute Multiple Databases Search”.  If there is not, click that box.  Next, click “Add”. 
 
 
 
 
 
Locate the first database that you wish to search, select it and click “Open”. 
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Repeat this process by clicking “Add”, selecting the second database you wish to  
 
search, and clicking “Open”. 
 
There is no limit to the number of databases you can search at one time.  However, the  
 
more databases you search simultaneously, the slower the search will be processed. 
 
You should see all of the databases that you selected to search listed as shown in the  
 
box to the below. 
  
 
 
 
When you are satisfied with the list of databases, click “OK”. 
 
Next, select “Search” on the top toolbar and proceed by searching for any alpha-numeric  
 
information or by structure as described in the appropriate sections of this guide  
 
(Sections 9 and 10, respectively).   
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Once your search is processed, a box as shown below will appear displaying the  
 
number of results found in each database. 
 
 
 
 
 
There are four options for viewing the search results, as described below. 
 
(a) Open DB: recommended if you want to view the search results from one 
database, and then view the search results from the next database individually.  
To view the results found in the first database, select it and click “Open DB”.  The first 
database will open and only the records found in that database matching your search 
criteria will be displayed. 
To subsequently view the search results found in the other database(s) searched, on the 
top toolbar select “Search” and then “Multiple DB Search Result”. When the box 
reappears displaying the number of results found in each database, select the second 
database instead of the first.  
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Then click “Open DB”.  The second database will open and only the records found in  
 
that database matching your search criteria will be displayed. 
 
(b) Merge All: recommended if you would like to merge all of the results into one file 
as a new database.  It will require you to save the file of the merged results 
before you can view them.   
A box as shown below will appear.  To merge the results into a new database, use the  
 
“Look in” drop-down menu to open the folder in which you wish to save the new  
 
database. 
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Change the “File name:” to reflect the name you wish to give the database, and then  
 
click “Open”.  When the box shown below appears, click “Yes”. 
 
 
 
 
 
Next, a box will appear prompting you to set a password to either edit (“Full Access  
 
Password”) or view (“Browse and Search Password”) the new database you created  
 
containing your search results.  
 
 
 
 
If you wish to set a password to edit or view the database, enter it and click “OK”. 
 
If you do not wish to set a password, leave all of the password fields blank and click 
“OK”. 
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To view the new database you created that contains only your search results, on the top 
toolbar select “Database”, “Open”, browse for the file and click “Open”. 
(c) Save: recommended if you will want to quickly load the same search results at  
 
another time. 
 
 
 
 
 
A box as shown above will appear.  Use the “Save in” drop-down menu to open the  
 
folder in which you wish to save the search.  Change the “File name:” to reflect the  
 
Name you wish to give the saved search, and then click “Save”. 
 
Note: the default file name that will be shown before you change it is *.MSR.  In order to  
 
save the file, you must remove the *.  If you do not remove the *, when you click “Save”  
 
nothing will happen. 
 
(d) Load: used to load a previously saved search.  Locate the saved search file that 
you wish to open, select it and click “Open”. 
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Important: When you are finished searching multiple databases, go back to “Search” on  
 
the top toolbar and select “Define Multiple DB List”.  Highlight each listed database and  
 
select “Remove”.  When finished, select “OK”.  If you do not do this, any search you  
 
perform will continue to be searched through the multiple databases you previously  
 
selected. 
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Important: When you are finished viewing your search results, on the top menu select  
 
“Search” and then “Retrieve All” to view all records in the database. 
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CHAPTER XI 
DATABASE CHALLENGES 
 
 
There were and will be challenges in populating and maintaining this database.  
Because multiple people use and populate the database, the highest risk is error in data 
entry.  At present there are eight different people adding data to the database.  These 
eight people represent five different countries and native languages.  This diversity is not 
expected to change and only further complicates the task of getting specific scientific 
information entered into the database in a precise and systematic way. 
If data is entered into the database incorrectly, the integrity and therefore the 
utility of the database will be jeopardized.  If the information in the database is 
inaccurate, searches will not return accurate results, resulting in limited functionality.  
Because it is necessary to allow for flexibility in the format of data entered into the 
database, it is not possible to check for errors in an automated manner.  Therefore, this 
risk is best mitigated by peer review.    
An unanticipated challenge of this project was multiple entries, or records, being 
entered for one compound.  Each chemist in the lab is responsible for entering the 
compounds that they isolate into the database.  As an example, Dr. Sloan Ayers isolated 
the compound pycnidione from the fungus coded MSX50044 and a record was created 
in the database for pycnidione capturing all of the data he generated.  Dr. Arlene Sy-
Cordero also isolated the compound pycnidione, but from a different fungus coded 
MSX60926.  She created a record in the database for pycnidione which includes all of 
the data that she generated for the compound. 
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Today, a search performed in the database for the compound pycnidione will 
produce two hits.  As the lab continues to isolate and characterize pure compounds, it is 
impossible to predict how many different chemists will isolate the same compound from 
different organisms.  Careful consideration was given to whether all of the data for one 
compound should be put into one record in the database, regardless of the chemist and 
source organism.  It was concluded, however, that the best method of organization is to 
continue having each chemist enter their data about each compound they isolate 
separately, even if this results in the database containing multiple records for the same 
compound.  Some records in the database may appear to be redundant, but each 
captures a unique set of data.  Users of the database will therefore have to thoughtfully 
select the appropriate data for their specific needs if a compound search produces more 
than one hit.    
Another database was created simultaneously by a mycologist in the same lab 
(Dr. Huzefa Raja) to capture all of the information and data relating to the collection of 
organisms.  A sample of the fields in the database include the collector, collection site, 
country, state, latitude, longitude, temperature, habitat, pH and elevation.  Once an 
organism is isolated, this database also includes details such as the fungus number, 
GenBank accession number for the organism, and the organism’s genus and species.  
Some of the information is redundant, because details such as the fungus number and 
organism’s taxonomy are entered into the ACD/Spectrum Database. 
Careful consideration was given to whether or not the databases should be 
combined, but it was concluded that the two different databases will be maintained, 
independent of one another.  The ACD/Spectrum Database will be used to locate data 
and information about any pure compound in the lab.  If more information about source 
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of a pure compound is needed, a search will have to be executed in the other database.  
Neither of these searches require a significant amount of time, and keeping the 
databases separate should help reduce the burden of having to enter an extensive 
quantity of information in either database.  Moreover, we concluded that the integrity of 
two specific data bases would be easier to maintain.  This could be considered akin to 
the saying that “you should not put all your eggs in one basket”.       
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CHAPTER XII 
COMPOUND STORAGE RESULTS 
 
 
To start this process, each vial was quickly cleaned via blowing air into the vial to 
remove any dust.  A label was prepared and placed on the outside of the vial, as shown 
in figure 5.  Labels specify the compound name, notebook ID, specimen number, and a 
barcode which, when scanned, provides the notebook ID.  Empty vials with labels affixed 
were weighed and the tare weight was neatly written on the vial.  The tare weight was 
also entered into an Excel spreadsheet in the event that it is ever removed or becomes 
illegible on the vial. 
Pure compounds were dissolved in either MeOH or CHCl3 and transferred into the 
appropriately labeled vial.  They were then vacuum-dried to evaporate the MeOH or 
CHCl3.  Vials containing the pure compounds were stored in vial file boxes, as shown in 
figure 6. 
The vial file boxes have been numbered sequentially.  Within each box, horizontal 
rows have been assigned a letter A through F and vertical rows have been assigned a 
letter 1 through 9.  This provides each pure compound with a unique letter and number 
combination, such as 1A5, indicating box 1, horizontal row A, vertical row 5.  This code 
allows all of the pure compounds to be catalogued and easily located.  These codes 
have been entered into the database and the vial file boxes were placed in the freezer 
for long-term storage.   
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Figure 7.  Labeled Vial for Pure Compound Storage. 
 
 
 
 
 
Figure 8.  Vial File Box of Pure Compounds. 
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As of February 20, 2012 there are approximately 161 appropriately labeled vials 
containing pure compounds that have been stored in a vial file box.  The number of vials 
stored is higher than the number of records in the database, mainly because some 
compounds have been stored in more than one vial.  This has occurred when, for 
example, a chemist takes a sample of the pure compound to perform an NMR 
experiment, and does not return the sample to the original vial.  Likewise, when the 
amount of a pure compound in the lab exceeds the 8 mL storage capacity of one vial, 
the compound is stored in two identically labeled vials.  The difference in the number of 
vials and the number of records in the database also occurs, to a lesser extent, because 
some compound data has not yet been uploaded to the database by the researcher. 
The biggest challenge of developing and implementing this storage system was 
locating all of the pure compounds in the lab.  Previously, all of the chemists used their 
own method for storing the pure compounds that they isolated.  Some of the chemists 
who have isolated pure compounds in the lab have since left the research group, making 
it a challenge to determine where and how their compounds were stored.  Additionally, 
as can be seen in figure 6, most of the chemists identified their compounds by writing on 
the vial with a Sharpie marker.  However, over time some of the writing has been 
smudged or erased, making it very difficult to determine what was in each vial. 
A protocol has been written for this process and is as follows. 
OBERLIES LAB PURE COMPOUND PROTOCOL 
1. Print a label for the vial. 
a. In the Label View software, open the “Cherilyn-mini-label” template 
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b. The field lengths will likely need adjusted.  To do this, click on the 
barcode.  Right click and select “Edit”.  Next, select “Define Field Lengths” 
on the lower right side of the pop-up box.   
c. Adjust the field lengths and enter the information in the fields as below: 
Field       Field Length Information to Enter in Field  
Notebook ID  13  Notebook ID  
Lengthy Text  23  Compound Name 
Weight   8  Fungus Number 
2. Make sure the inside of the pure compound vial is clean, and affix your label to it. 
3. Weigh the clean, empty, labeled vial and neatly write the weight in grams on the 
lower part of the vial with a Sharpie. 
4. Open the excel work book titled “Vial Weights” in the Oberlies Lab Group folder 
on the N drive.  Enter your compound name, notebook ID and the weight in 
grams of your empty, labeled vial there. 
5. Transfer your pure compound into the vial. 
6. Weigh the vial with your dry, pure compound in it.  Write the amount of the 
compound, in milligrams, neatly on the middle of the vial with a Sharpie. 
7. Place the vial into a vial file box. 
8. Note the Box Number (vial file box should say “Box 1”, for example, on top).  If it 
is a new vial file box, use a permanent marker to write a box number onto the 
paper insert so that it is viewable from the outside.  Boxes are to be numbered 
sequentially. 
9. Note the lettered horizontal row and numbered vertical row in which your 
compound vial is placed. 
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10. Enter the box number, row letter and row number into the pure compound 
database in that order.  Example for formatting: 1A5 would be the compound in 
box 1, horizontal row A, vertical row 5. 
11. Place the box in the appropriate freezer, where all other pure compound vial file 
boxes are stored.  
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CHAPTER XIII 
CONCLUSION 
 
 
Using ACD/Spectrum Database software, a library of natural product pure 
compounds was created.  While challenges with the database, such as redundant or 
erroneous entries, will continue to be present, they should be less frequent if the protocol 
is properly followed and are able to be mitigated through peer-review.  The compounds 
were also physically stored in an organized and systematic manner that will allow the 
compounds to be leveraged into other bioassays in the future.  Protocols were written 
that will aide in the long-term maintenance of the database and compound storage 
system.  Moreover, the frame work of the database can be leveraged into other needs 
that develop over time.   
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